WASHINGTON, D.C. — Questex announced the launch of three new life sciences events in 2025, which are meant to kickstart collaboration and change in the industry.
Fierce Pharma Engage will be held April 29-May 1 in San Diego and bring together pharma and biotech executives to explore innovative technologies and develop tailored success strategies.
Fierce Pharma Week, set for Sept. 8-11 in Philadelphia, will combine existing events — including Digital Pharma East, New Product Planning Summit, Pharma PR & Communications Summit East and Medical Affairs Strategic Summit East — and explore integrating marketing and sales, medical affairs and communications.
Related. Questex Expects More Than 13% Year-Over-Year Growth and Enhances Portfolio in 2024
Fierce Biotech Week, scheduled for Oct. 7-9 in Boston, will merge Fierce Biotech Summit, Trial Master File Summit and Fierce Clinical Summit, and host C-suite leadership discussions around research and development priorities, drug development optimization and capital raising and partnership strategies.
“2024 was incredibly successful for the Digital Pharma East, New Product Planning Summit, Pharma PR & Communications Summit East and Medical Affairs Strategic Summit East events. All of the events experienced record attendance and revenue, which resulted in double digit growth. With heightened interest from the pharma community in these critical go-to-market areas, we felt it was the right time to bring our audience together in one venue for better collaboration, education and networking. All of these communities are responsible for the successful commercialization of pharmaceutical products and now they can collaborate in one centralized location. The feedback we received from exhibitors and sponsors is extremely positive, as many of them target multiple communities in the go-to-market area and the event will allow for continued strong ROI. In addition to the new event, Fierce Pharma delivers news and information to the pharma community 365 days a year through our website and newsletters,” Rhiannon James, Group President, Pharma, Healthcare & Technology, said.
